Get the Stockscreener App
0.2263
9.04%
-0.0225
Pre-market:
.23
0.0037
+1.63%
In 8 Bio Inc Stock (INAB) Latest News
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders - Joplin Globe
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule - GlobeNewswire
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts - Yahoo Finance
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - Yahoo Finance
Canadian North Resources Inc. Expands Metallurgical Programs Applying Low-carbon Footprint Bioleaching Technology on Ferguson Lake Ni-Cu-Co PGE project - Yahoo Canada Finance
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Global Nucleic Acid Amplification Testing Market to Grow Rapidly at an ~8% CAGR by 2032 | DelveInsight - GlobeNewswire
Genetic Medicine Pioneer Passage Bio Sets March Investor Conference Schedule - StockTitan
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy - Defense World
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - Yahoo Finance
What's Going On With Gene Therapy Company Bluebird Bio Stock Today? - Benzinga
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - GlobeNewswire Inc.
KALA BIO Announces Chief Executive Officer Transition - GlobeNewswire
Plug Power (NASDAQ:PLUG) Enters Into Standby Equity Purchase Agreement with YA II PN, LTD - Defense World
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Mustang Bio Closes $8 Million Public Offering - citybiz
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire
Mustang Bio Announces Closing of $8 Million Public Offering - The Manila Times
Mustang Bio, Inc. Completes Public Offering, Raising Approximately $8 Million for Cancer Cell Therapy Development - Nasdaq
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - The Manila Times
Bluebird bio Inc (NASDAQ: BLUE) Now Carries A 12-Month Price Target Of $25. - Marketing Sentinel
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Quantisnow
Mustang Bio Announces Pricing of $8 Million Public Offering - GlobeNewswire
Capital Raise Alert: Mustang Bio Secures Fresh $8M Funding Through Strategic Share & Warrant Offering - StockTitan
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - Quantisnow
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - Quantisnow
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering - Quantisnow
Passage Bio shares transition to Nasdaq Capital Market - Investing.com
Annovis Bio, Inc. Announces Proposed Public Offering - Quantisnow
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - Yahoo Finance
SAB BIO Announces Positive Topline Phase 1 Clinical Results - GlobeNewswire
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire
Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE) - Yahoo Finance UK
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024 - Defense World
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8% – Time to Buy? - Defense World
Mustang Bio Announces Reverse Stock Split - GlobeNewswire
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Cadenza Bio, Inc. Announces Members of the Women's Health Scientific Advisory Board - Chicago Star Media
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Pivot Bio Announces Ryan Degnan as Head of Growth - PR Newswire
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - The Bakersfield Californian
7 Best Biotech Stocks to Buy for 2025 | Investing - U.S News & World Report Money
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):